DOCSLIB.ORG

Efficacy and Safety of Sonic Hedgehog Pathway Inhibitors in Cancer

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Efficacy and Safety of Sonic Hedgehog Pathway Inhibitors in Cancer HHS Public Access Author manuscript Author ManuscriptAuthor Manuscript Author Drug Saf Manuscript Author . Author manuscript; Manuscript Author available in PMC 2020 February 01. Published in final edited form as: Drug Saf. 2019 February ; 42(2): 263–279. doi:10.1007/s40264-018-0777-5. Efficacy and safety of sonic hedgehog pathway inhibitors in cancer Richard L Carpenter1,2,3,* and Haimanti Ray2 1Department of Biochemistry and Molecular Biology, Indiana University School of Medicine, 1001 E. 3rd St, Bloomington, IN 47405 2Medical Sciences, Indiana University School of Medicine, 1001 E. 3rd St, Bloomington, IN 47405 3Simon Cancer Center, Indiana University School of Medicine, 1001 E. 3rd St, Bloomington, IN 47405 Abstract The hedgehog pathway, for which sonic hedgehog (Shh) is the most prominent ligand, is highly conserved and is tightly associated with embryonic development in a number of species. This pathway is also tightly associated with development of several types of cancer, including basal cell carcinoma and acute promyelocytic leukemia (APL) among many others. Inactivating mutations in Patched 1 (PTCH1), leading to ligand-independent pathway activation, are frequent in several cancer types but most prominent in basal cell carcinoma. This has led to the development of several compounds targeting this pathway as a cancer therapeutic. These compounds target the inducers of this pathway in Smoothened (SMO) and the GLI transcription factors, although targeting SMO has had the most success. Despite the many attempts at targeting this pathway, there are only three FDA-approved drugs for cancers that affect the Shh pathway. Two of these compounds, vismodegib and sonidegib, target SMO to suppress signaling from either PTCH1 or SMO mutations that lead to upregulation of the pathway. The other approved compound is arsenic trioxide (ATO), which can suppress this pathway at the level of the GLI proteins, although current evidence suggests it also has other targets. This review focuses on the efficacy and safety of these clinically-approved drugs targeting the Shh pathway along with a discussion on other Shh pathway inhibitors being developed. 1. Introduction The hedgehog pathway is a highly conserved signaling pathway that is linked to many biological processes. This signaling pathway has been linked to development in many species, including humans (1). It has been linked to growth and patterning in many of these multicellular species including the development of the neural system and bone development (2, 3). The hedgehog pathway and its components have also been linked to several diseases, prominently including human cancer (4). Because of the importance of this pathway to human cancer, there have been several attempts to target this pathway for cancer therapies *Corresponding Author: [email protected]; Phone: (812) 855-8214. Conflict of Interest: Richard L Carpenter and Haimanti Ray have no conflicts of interests to declare. Carpenter and Ray Page 2 with few successes and many failures. In this review, we aim to provide an update on the Author ManuscriptAuthor Manuscript Author Manuscript Author Manuscript Author successful agents targeting the hedgehog pathway that have been FDA approved for treatment in human cancers. We will also briefly discuss agents that are currently being developed to target this pathway for the treatment of cancer. 2. The Hedgehog Pathway in Cancer Mammalian hedgehog signaling can be initiated by three unique ligands in Sonic Hedgehog (Shh), Indian hedgehog, and Desert hedgehog. However, Shh is the most widely expressed and also the most potent of these ligands (1, 5). The ligand Shh is expressed as an inactive full-length protein that is proteolytically cleaved to two proteins and the N-terminal 19 kDa fragment is the active Shh ligand (6). The receptor for this active Shh ligand is Patched1 (PTCH1), a 12-transmembrane protein that binds Shh ligand. Binding of Shh to PTCH1 relieves repression of Smoothed (SMO) by PTCH1 thereby activating SMO signaling activity (Figure 1). The activation of SMO ultimately decreases the interaction between suppressor of fused homolog (SUFU) and GLI proteins that allows GLI proteins to enter the nucleus and bind transcriptional targets to regulate cellular gene expression. There are three GLI isoforms in mammals in GLI1-3 wherein gene expression can be induced by GLI1 and repressed by GLI3 whereas GLI2 can regulate expression in either direction. The GLI proteins are the terminal effectors of the Shh signaling pathway and regulate genes that control organismal patterning and development. Many of the genes regulated by GLI proteins are co-opted by cancer cells as they regulate several cancer-related processes including proliferation, migration and invasion, as well as neovascularization (4). There have been numerous reports of genetic alterations in key components of the Shh pathway in different tumor types that leads to constitutive signaling of this pathway and that paracrine signaling of Shh may be an important factor in multiple tumor types (7, 8). While there are reports of the Shh pathway being modified in several tumor types such as breast, pancreatic, colorectal, and rhabdomyosarcoma among several, genetic alterations in this pathway are most consistently seen in basal cell carcinomas (BCCs) and medulloblastomas (9–19). The genetic alterations in this pathway are commonly loss-of-function changes to suppressors of the pathway (e.g. PTCH1, SUFU) or gain-of-function changes to promotors of the pathway (e.g. SMO, GLI). This is very prevalent in BCC as PTCH1 has a gene inactivating alteration in 73% of these tumors while SMO has a genetic activation in 20% (20). Therapies targeted to the Shh pathway primarily inhibit the components that promote signaling flux through the pathway including Shh ligand itself, SMO, and GLI proteins. The most successful strategy has been to target SMO with small molecule compounds and the two FDA-approved drugs targeting this pathway use this strategy. Targeting SMO in BCC, for instance, has the potential to target the large percentage of these tumors that harbor inactivating alterations to PTCH1 or activating mutations to SMO. There are also inactivating alterations to SUFU in 8% of BCCs (20) and GLI1 is amplified in several tumor types (4) but SMO inhibitors are unlikely to show efficacy against these populations. There have been attempts to develop inhibitors to Shh and GLI1 but these have yet to make it past clinical trials. Drug Saf. Author manuscript; available in PMC 2020 February 01. Carpenter and Ray Page 3 Author ManuscriptAuthor 3. Manuscript Author Currently Manuscript Author Approved Shh Manuscript Author Pathway Inhibitors The first FDA-approved drug for cancer that targeted the Shh pathway was arsenic trioxide (ATO) in 2000, which was approved for treatment of acute promyelocytic leukemia (APL) (21). While it has been proven to have significant effects suppressing the Shh pathway, it likely also targets other mechanisms promoting APL development and progression. Despite, ATO being the first FDA-approved drug that does have effects on the Shh pathway, the first FDA-approved agent that was specifically designed to target the Shh pathway was vismodegib (GDC-449), which was originally discovered in 2009 and later approved for treatment of basal cell carcinoma in 2012 (22, 23). A year later in 2010, sonidegib (LDE225) was discovered and was later also approved for treatment of basal cell carcinoma in 2015 (24, 25). These are currently the only approved agents targeting the Shh pathway with indications for cancer (Table 1). 3.1. Arsenic Trioxide (ATO) Arsenic formulations have been used for their beneficial therapeutic effects as far back as the 17th century (21). However, chronic exposure to arsenic is also labeled as a carcinogen and has been shown to promote solid tumors (26, 27). As an anti-cancer therapeutic, ATO has been shown to suppress growth in preclinical models in many tumor types including breast cancer, pancreatic cancer, colon cancer, acute promyelocytic leukemia (APL), melanomas, glioblastoma, and medulloblastoma among others (28–32). Arsenic trioxide (ATO) was initially approved as a therapy for patients with acute promyelocytic leukemia (APL) who are refractory or have relapsed on retinoid and anthracycline chemotherapy (21). This approval came after two landmark trials wherein APL patients had become resistant to standard therapies of chemotherapy or all-trans retinoic acid (ATRA) (33, 34). ATO treatment increased the complete response rate from <40% to >90% and extended the time of this complete response (33, 34). ATO has since been approved for patients with low- and intermediate-risk APL by the EU and approved by the US FDA in combination with ATRA for newly-diagnosed low-risk APL with the t(15; 17) translocation of PML-RARA. ATO has been investigated in several other tumor types, including those with increased Shh dependence, but APL is currently the only indication approved for ATO. 3.1.1. Mechanism of action: APL develops in 95% of cases due to fusion of the promyelocytic gene (PML) on chromosome 15 with the retinoic acid receptor alpha gene (RARA) on chromosome 17 resulting in the PML-RARA t(15; 17) fusion protein (35). The PML-RARA fusion protein acts a transcriptional repressor to block myeloid differentiation. Early studies indicated ATO was effective against PML as exposure to ATO led to decreased levels of PML-RARA protein, as well as other cell survival proteins, and differentiation (29, 36–38). These results led to studies that found significant clinical benefit for APL patients receiving ATO and eventual FDA approval (37, 39). Despite this obvious link of ATO affecting the precise mechanism leading to APL, recent studies have also indicated that ATO has an effect in suppressing the Shh pathway. One of these early findings indicated that ATO suppressed GLI transcriptional activity that was not linked to cell viability, suggesting ATO Drug Saf. Author manuscript; available in PMC 2020 February 01. Carpenter and Ray Page 4 was specifically targeting the Shh pathway (40).
Load more

Recommended publications
  • Cyclopamine Inhibition of Sonic Hedgehog Signal Transduction Is
    Developmental Biology 224, 440–452 (2000) doi:10.1006/dbio.2000.9775, available online at http://www.idealibrary.com on View metadata, citation and similar papers at core.ac.uk brought to you by CORE Cyclopamine Inhibition of Sonic Hedgehog Signalprovided by Elsevier - Publisher Connector Transduction Is Not Mediated through Effects on Cholesterol Transport John P. Incardona,* William Gaffield,† Yvonne Lange,‡ Adele Cooney,§ Peter G. Pentchev,§ Sharon Liu,¶ John A. Watson,¶ Raj P. Kapur,ሻ and Henk Roelink*,1 *Department of Biological Structure and Center for Developmental Biology and ࿣Department of Pathology, University of Washington, Seattle, Washington 98195; †Western Regional Research Center, ARS, United States Department of Agriculture, Albany, California 94710; ‡Department of Pathology, Rush–Presbyterian–St. Luke’s Medical Center, Chicago, Illinois 60612; §Developmental and Metabolic Neurobiology Branch, NINDS, National Institutes of Health, Bethesda, Maryland 20892; and ¶Department of Biochemistry and Biophysics, University of California at San Francisco, San Francisco, California 94143 Cyclopamine is a teratogenic steroidal alkaloid that causes cyclopia by blocking Sonic hedgehog (Shh) signal transduction. We have tested whether this activity of cyclopamine is related to disruption of cellular cholesterol transport and putative secondary effects on the Shh receptor, Patched (Ptc). First, we report that the potent antagonism of Shh signaling by cyclopamine is not a general property of steroidal alkaloids with similar structure. The structural features of steroidal alkaloids previously associated with the induction of holoprosencephaly in whole animals are also associated with inhibition of Shh signaling in vitro. Second, by comparing the effects of cyclopamine on Shh signaling with those of compounds known to block cholesterol transport, we show that the action of cyclopamine cannot be explained by inhibition of intracellular cholesterol transport.
    [Show full text]
  • Potential High-Impact Interventions Report Priority Area 02: Cancer
    AHRQ Healthcare Horizon Scanning System – Potential High-Impact Interventions Report Priority Area 02: Cancer Prepared for: Agency for Healthcare Research and Quality U.S. Department of Health and Human Services 540 Gaither Road Rockville, MD 20850 www.ahrq.gov Contract No. HHSA290201000006C Prepared by: ECRI Institute 5200 Butler Pike Plymouth Meeting, PA 19462 December 2012 Statement of Funding and Purpose This report incorporates data collected during implementation of the Agency for Healthcare Research and Quality (AHRQ) Healthcare Horizon Scanning System by ECRI Institute under contract to AHRQ, Rockville, MD (Contract No. HHSA290201000006C). The findings and conclusions in this document are those of the authors, who are responsible for its content, and do not necessarily represent the views of AHRQ. No statement in this report should be construed as an official position of AHRQ or of the U.S. Department of Health and Human Services. This report’s content should not be construed as either endorsements or rejections of specific interventions. As topics are entered into the System, individual topic profiles are developed for technologies and programs that appear to be close to diffusion into practice in the United States. Those reports are sent to various experts with clinical, health systems, health administration, and/or research backgrounds for comment and opinions about potential for impact. The comments and opinions received are then considered and synthesized by ECRI Institute to identify interventions that experts deemed, through the comment process, to have potential for high impact. Please see the methods section for more details about this process. This report is produced twice annually and topics included may change depending on expert comments received on interventions issued for comment during the preceding 6 months.
    [Show full text]
  • Investigator Initiated Study IRB-29839 an Open-Label Pilot Study To
    Investigator Initiated Study IRB-29839 An open-label pilot study to evaluate the efficacy and safety of a combination treatment of Sonidegib and BKM120 for the treatment of advanced basal cell carcinomas Version 05 September 2016 NCT02303041 DATE: 12Dec2018 1 Coordinating Center Stanford Cancer Center 875 Blake Wilbur Drive Stanford, CA 94305 And 450 Broadway, MC 5334 Redwood City, CA 94603 Protocol Director and Principal Investigator Anne Lynn S Chang, MD, Director of Dermatological Clinical Trials 450 Broadway St, MC 5334 Redwood City, CA 94603 [email protected] Co-Investigator Anthony Oro, MD PhD 450 Broadway St, MC 5334 Redwood City, CA 94603 [email protected] Biostatistician Shufeng Li, MS 450 Broadway St, MC 5334 Redwood City, CA 94603 [email protected] Study Coordinator Ann Moffat 450 Broadway St, MC 5334 Redwood City, CA 94603 [email protected] 2 Table of Contents 1 Background ................................................................. 7 1.1 Disease Background ..................................................... 7 1.2 Hedgehog Pathway and mechanism of action ............................... 7 1.3 PI3K Pathway and mechanism of action ................................... 9 1.4 Sonidegib Compound Information ............ Error! Bookmark not defined. 1.4.1 Preclinical Studies for Sonidegib ....................................................................11 1.4.2 Muscular system...............................................................................................13 1.4.3 Skeletal system ................................................................................................13
    [Show full text]
  • Genomic Oncology: Moving Beyond the Tip of the Iceberg Jane De Lartigue, Phd
    FeatureCommunity Report Genomic oncology: moving beyond the tip of the iceberg Jane de Lartigue, PhD istorically, cancer has been diagnosed and in patients with lung cancer, even the most efec- treated on the basis of the tissue of ori- tive targeted therapies can fail if used in the wrong Hgin. Te promise of personalized therapy, patient population.5,6 matched more precisely to an individual’s tumor, In recognition of this issue, the oncology feld has was ushered in with the development of molecularly developed molecular biomarkers that can predict targeted therapies, based on a greater understanding response, or lack thereof, to targeted therapy. Drugs of cancer as a genomic-driven disease. Here, we dis- are now commonly being evaluated in trials that cuss some of the evolution of genomic oncology, the select eligible patients on the basis of biomarker pos- inherent complexities and challenges, and how novel itivity, and a number of companion diagnostics have clinical trial designs are among the strategies being been codeveloped to assist in these eforts (Table 1). developed to address them and shape the future of Notable successes include the development of the personalized medicine in cancer. monoclonal antibody trastuzumab for patients with breast cancers that have human epidermal growth The evolution of genomic oncology factor receptor 2 (HER2) gene amplifcation or In the 15 years since the frst map of the human HER2 protein overexpression,7 and the small mol- genome emerged, genetics has become an inte- ecule BRAF kinase inhibitor
    [Show full text]
  • FDA-Approved Content Report Section 1
    SAMPLE REPORT New FDA-Approved Broad Companion Diagnostic for Solid Tumors FDA-Approved Content Report Section 1 1 FDA-Approved Therapies PATIENT TUMOR TYPE TRF# List of FDA-approved Jane Sample Lung adenocarcinoma TRFXXXXXX companion diagnostics to PATIENT PHYSICIAN SPECIMEN identify patients who may DISEASE Lung adenocarcinoma ORDERING PHYSICIAN Not Given SPECIMEN SITE Not Given NAME Not Given MEDICAL FACILITY Not Given SPECIMEN ID Not Given benefi t from associated DATE OF BIRTH Not Given ADDITIONAL RECIPIENT Not Given SPECIMEN TYPE Not Given SEX Female MEDICAL FACILITY ID Not Given DATE OF COLLECTION Not Given therapies MEDICAL RECORD # Not Given PATHOLOGIST Not Given SPECIMEN RECEIVED Not Given CDx Associated Findings 1 GENOMIC FINDINGS DETECTED FDA-APPROVED THERAPEUTIC OPTIONS 2 All Other Biomarkers EGFR L858R Gilotrif® (Afatinib) All other biomarkers, Iressa® (Gefitinib) including tumor mutational Tarceva® (Erlotinib) burden (TMB) and 2 microsatellite instability (MSI), without companion OTHER ALTERATIONS & BIOMARKERS IDENTIFIED Results reported in this section are not prescriptive or conclusive for labeled use of any specific therapeutic product. See diagnostic claims professional services section for additional information. Microsatellite Status MS-Stable PTCH1 T416S Tumor Mutation Burden 11 Muts/Mb RBM10 Q494* CDKN2A/B loss TP53 R267P EGFR amplification § Refer to appendix for limitation statements related to detection of any copy number alterations, gene rearrangements, MSI or TMB result in this section. Please refer to appendix
    [Show full text]
  • Overcoming the Challenges of Oral Oncolytic Therapies with a Specialized Crew
    Navigating Safely Through Uncharted Waters: Overcoming the Challenges of Oral Oncolytic Therapies with a Specialized Crew Mitchell E. Hughes, PharmD, BCPS, BCOP Clinical Pharmacy Specialist-Hematology/Oncology The Abramson Cancer Center for Advanced Medicine at Penn Medicine Objectives At the completion of this activity, the participant will be able to: 1. List risks associated with dispensing oral oncolytic agent 2. Recognize potential barriers to implementation of a vigilance program for oral oncolytic agents 3. Discuss strategies to improve safety and communications involved with dispensing oral oncolytic agents 2 Disclosure “I have not received any commercial or financial support for this program” 3 Oral Chemotherapy Definition “Any drug you take by mouth to treat cancer. Oral chemo is not given to you with a needle. It’s a liquid or pill that you swallow.” “Chemo you swallow is as strong as other forms of chemo and works just as well. You take oral chemo at home” “But oral chemo drugs cost a lot” –The American Cancer Society 4 Image available from: https://localtvwiti.files.wordpress.com/2014/03/chemo-pills.jpg?quality=85&strip=all https://www.cancer.org/treatment/treatments-and-side-effects/treatment-types/chemotherapy/oral-chemotherapy.html Misconceptions Oral chemotherapy is less toxic than intravenous (IV) chemotherapy Oral chemotherapy requires less monitoring than IV Patients will be able to start therapy the day oral chemotherapy is prescribed Oral chemotherapy does not involve any hazardous precautions 5 Image available
    [Show full text]
  • An Investigator-Initiated Open-Label Trial of Sonidegib in Advanced Basal Cell Carcinoma Patients Resistant to Vismodegib Christina Danial, Kavita Y
    Published OnlineFirst November 6, 2015; DOI: 10.1158/1078-0432.CCR-15-1588 Clinical Trial Brief Report Clinical Cancer Research An Investigator-Initiated Open-Label Trial of Sonidegib in Advanced Basal Cell Carcinoma Patients Resistant to Vismodegib Christina Danial, Kavita Y. Sarin, Anthony E. Oro, and Anne Lynn S. Chang Abstract Purpose: To assess the tumor response to the smoothened sive disease with sonidegib. Three patients experienced stable (SMO) inhibitor, sonidegib (LDE225), in patients with an disease and discontinued sonidegib either due to adverse events advanced basal cell carcinoma (BCC) resistant to treatment with (n ¼ 1) or due to election for surgery (n ¼ 2). The response of one vismodegib (GDC0449). patient was not evaluable. SMO mutations with in vitro data Experimental Design: Nine patients with an advanced suggesting resistance to Hh pathway inhibition were identified BCC that was previously resistant to treatment with vismode- in 5 patients, and none of these patients experienced responses gib were given sonidegib in this investigational, open- while on sonidegib. label study. Tumor response was determined using the Conclusion: Patients with advanced BCCs that were response evaluation criteria in solid tumors. SMO mutations previously resistant to treatment with vismodegib similarly were identified using biopsy samples from the target BCC demonstrated treatment resistance with sonidegib. Patients location. who have developed treatment resistance to an SMO inhibitor Results: The median duration of treatment with sonidegib was may continue to experience tumor progression in response to 6 weeks (range, 3–58 weeks). Five patients experienced progres- other SMO inhibitors. Clin Cancer Res; 1–5. Ó2015 AACR. Introduction Sonidegib (LDE225) is a new SMO inhibitor approved in 2015 by the FDA for locally advanced BCCs.
    [Show full text]
  • Combination of Ponatinib with Hedgehog Antagonist Vismodegib for Therapy-Resistant BCR-ABL1–Positive Leukemia
    Published OnlineFirst January 14, 2013; DOI: 10.1158/1078-0432.CCR-12-1777 Clinical Cancer Cancer Therapy: Preclinical Research See related commentary by Dao and Tyner, p. 1309 Combination of Ponatinib with Hedgehog Antagonist Vismodegib for Therapy-Resistant BCR-ABL1–Positive Leukemia Seiichiro Katagiri1, Tetsuzo Tauchi1, Seiichi Okabe1, Yosuke Minami2, Shinya Kimura3, Taira Maekawa4, Tomoki Naoe2, and Kazuma Ohyashiki1 Abstract Purpose: The Hedgehog signaling pathway is a key regulator of cell growth and differentiation during development. Whereas the Hedgehog pathway is inactive in most normal adult tissues, Hedgehog pathway reactivation has been implicated in the pathogenesis of several neoplasms including BCR-ABL1–positive leukemia. The clear link between the Hedgehog pathway and BCR-ABL1–positive leukemia led to an effort to identify small molecules to block the pathway. Experimental Design: We investigated the combined effects of vismodegib and ponatinib, a pan-ABL1 kinase inhibitor, in nonobese diabetic/severe-combined immunodeficiency (NOD/SCID) repopulating T315I BCR-ABL1–positive cells in vitro and in vivo. Results: We observed that combination with vismodegib and ponatinib helps to eliminate therapy- resistant NOD/SCID repopulating T315I BCR-ABL1–positive cells. The percentage of CD19-positive leukemia cells in peripheral blood was significantly lower in vismodegib þ ponatinib–treated mice than that of the vehicle or ponatinib alone (P < 0.001). Spleen weights were also lower in vismodegib þ ponatinib–treated mice than in ponatinib alone (P < 0.05). Overall tumor burden, as assessed by BCR-ABL mRNA from bone marrow cells, was significantly lower in vismodegib þ ponatinib–treated mice than in ponatinib alone (P < 0.005).
    [Show full text]
  • Sonidegib for the Treatment of Advanced Basal Cell Carcinoma
    Zurich Open Repository and Archive University of Zurich Main Library Strickhofstrasse 39 CH-8057 Zurich www.zora.uzh.ch Year: 2016 Sonidegib for the treatment of advanced basal cell carcinoma Ramelyte, Egle ; Amann, Valerie C ; Dummer, Reinhard DOI: https://doi.org/10.1080/14656566.2016.1225725 Posted at the Zurich Open Repository and Archive, University of Zurich ZORA URL: https://doi.org/10.5167/uzh-125862 Journal Article Accepted Version Originally published at: Ramelyte, Egle; Amann, Valerie C; Dummer, Reinhard (2016). Sonidegib for the treatment of advanced basal cell carcinoma. Expert Opinion on Pharmacotherapy, 17(14):1963-1968. DOI: https://doi.org/10.1080/14656566.2016.1225725 Sonidegib for the treatment of advanced basal cell carcinoma Egle Ramelyte1,2,MD, Valerie C. Amann1, MD, Reinhard Dummer 1, MD, 1 - Department of Dermatology, University Hospital Zurich, Zurich, Switzerland 2 - Vilnius University, Centre of Dermatovenereology, Vilnius, Lithuania Corresponding author: Reinhard Dummer, MD University Hospital of Zurich Department of Dermatology Gloriastrasse 31 CH-8091, Zürich, Switzerland Phone: 41-44-255-2507 Fax: 41-44-255-8988 E-mail: [email protected] 1 Abstract Introduction. Advanced and metastatic basal cell carcinomas (BCCs) are rare but still present a severe medical problem. These tumors are often disfiguring and impact the quality of life by pain or bleeding. Based on discovery of the hedgehog (Hh) signaling pathway and it’s role in pathogenesis of BCCs, Smoothened (SMO) inhibitors have been developed with Sonidegib being the 2nd in class. It is the only Hh pathway inhibitor investigated in a randomized trial accompanied by pharmacodynamic investigations. Also, the disease assessment criteria applied were more stringent than those used in trials of 1st developed SMO inhibitor – vismodegib, and required annotated photographs, MRI as well as multiple biopsies in case of regression.
    [Show full text]
  • Imatinib (Gleevec™)
    Biologicals What Are They? When Did All of this Happen? There are Clear Benefits. Are there also Risks? Brian J Ward Research Institute of the McGill University Health Centre Global Health, Immunity & Infectious Diseases Grand Rounds – March 2016 Biologicals Biological therapy involves the use of living organisms, substances derived from living organisms, or laboratory-produced versions of such substances to treat disease. National Cancer Institute (USA) What Effects Do Steroids Have on Immune Responses? This is your immune system on high dose steroids projects.accessatlanta.com • Suppress innate and adaptive responses • Shut down inflammatory responses in progress • Effects on neutrophils, macrophages & lymphocytes • Few problems because use typically short-term Virtually Every Cell and Pathway in Immune System ‘Target-able’ (Influenza Vaccination) Reed SG et al. Nature Medicine 2013 Nakaya HI et al. Nature Immunology 2011 Landscape - 2013 Antisense (30) Cell therapy (69) Gene Therapy (46) Monoclonal Antibodies (308) Recombinant Proteins (93) Vaccines (250) Other (81) http://www.phrma.org/sites/default/files/pdf/biologicsoverview2013.pdf Therapeutic Category Drugs versus Biologics Patented Ibuprofen (Advil™) Generic Ibuprofen BioSimilars/BioSuperiors ? www.drugbank.ca Patented Etanercept (Enbrel™) BioSimilar Etanercept Etacept™ (India) Biologics in Cancer Therapy Therapeutic Categories • Hormonal Therapy • Monoclonal antibodies • Cytokine therapy • Classical vaccine strategies • Adoptive T-cell or dendritic cells transfer • Oncolytic
    [Show full text]
  • Manufacturer Patient Assistance Programs
    Manufacturer Patient Assistance Programs * Provisional Bridging Programs August 2021 highlighted below in blue For medications currently not funded per the BC Cancer Benefit Drug List - http://www.bccancer.bc.ca/systemic-therapy-site/documents/policy%20and%20forms/benefit%20drug%20list.pdf Disclaimer: BC Cancer intends to keep the information on this document as up to date as possible but cannot guarantee that the programs are all available as listed. Contact your local Drug Access Navigator (DAN) for more information UPDATES: New MPAP/Compassionate Access Open: Abiraterone-JAMP, Abiraterone-Sandoz, Everolimus-Sandoz, Gefitinib-JAMP, Gefinitib-Sandoz, Imatinib-JAMP, Encorafenib (Braftovi), Binimetinib (Mektovi), Pralsetinib (Gavreto), Trastuzumab Deruxtecan (Enhertu) Provisional Bridging/Compassionate Access Closed: MPAP Closed: Additional Updates: Drug Manufacturer / PAP Name Contact Information Support Offered Route Strength DIN Abemaciclib (Verzenio) Lilly Phone 1.855.545.5922 Compassionate supply may be available PO 50mg 02487098 * Provisional Bridging Program Lilly Patient Support Program Fax 1.844.503.7749 Financial assistance for patients with or without private insurance may be available PO 100mg 02487101 Email [email protected] PO 150mg 02487128 Web PO 200mg 02487136 Abiraterone (Zytiga) Janssen Phone 1.844.511.2616 Compassionate supply may be available PO 250mg 02371065 * Provisional Bridging Program Janssen BioAdvance Patient Assistance Program Fax 1.855.629.7100 Financial assistance for patients with or without private
    [Show full text]
  • Assessment Report
    25 June 2015 EMA/472165/2015 Committee for Medicinal Products for Human Use (CHMP) Assessment report Odomzo International non-proprietary name: sonidegib Procedure No. EMEA/H/C/002839/0000 Note Assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted. 30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5555 Send a question via our website www.ema.europa.eu/contact An agency of the European Union © European Medicines Agency, 2015. Reproduction is authorised provided the source is acknowledged. Table of contents 1. Background information on the procedure ............................................ 7 1.1. Submission of the dossier ...................................................................................... 7 1.2. Manufacturers ...................................................................................................... 8 1.3. Steps taken for the assessment of the product ......................................................... 8 2. Scientific discussion .............................................................................. 9 2.1. Introduction......................................................................................................... 9 2.2. Quality aspects .................................................................................................. 11 2.2.1. Introduction .................................................................................................... 11
    [Show full text]